Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Joost J.C. Verhoeff(University Medical Center Utrecht), Wouter R. van Furth(Leiden University Medical Center), Lukas J.A. Stalpers, An Claes(Utrecht University), Olaf van Tellingen(Dutch Cancer Society), Myra E. van Linde(Amsterdam Neuroscience), D. J. Richel(Unknown), William P. J. Leenders(Radboud University Nijmegen)
Cited by 193
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884